Share
Paolo Paoletti
Myricx Bio, a UK-based biotech company pioneering the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), announced the appointment of Paolo Paoletti, MD, to its Board of Directors as an Independent Non-Executive Director (NED).
Following a successful £90m (US$114m) Series A financing, Myricx has strengthened its leadership team and relocated to new facilities at the London Innovation Centre in Canary Wharf.
Paolo Paoletti, a renowned figure in oncology and precision medicine, previously served as the first President of GSK Oncology, where he played a key role in developing seven new cancer therapies. He also led GammaDelta Therapeutics through to its clinical stage before its acquisition by Takeda in 2022.
Chris Martin, Chairman of Myricx Bio, welcomed Paoletti, stating that his deep expertise in R&D and commercialization will be instrumental as the company progresses its N-Myristoyltransferases inhibitor (NMTi) ADCs into clinical development.
